2 transcripts
PRPO
Earnings call transcript
NASDAQ
2024 Q2
19 Aug 24
continued on that track, and in Q3 to date, we are exceeding our breakeven target for the Pathology division. We have a solid team. Our existing customer
PRPO
Earnings call transcript
NASDAQ
2023 Q2
17 Aug 23
is approximately 45% of the target. However, in contrast to the steady and gradual growth on the pathology side, on the product side, revenue increase in the set
- Prev
- 1
- Next